Literature DB >> 26501506

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.

Jonathan Gooblar1, Catherine M Roe2, Natalie J Selsor3, Matthew J Gabel4, John C Morris5.   

Abstract

IMPORTANCE: Results of Alzheimer disease (AD) research assessments typically are not disclosed to participants. Recent research has suggested interest in disclosure, but, to our knowledge, few studies have accounted for awareness of potential benefits and limitations of disclosure.
OBJECTIVE: To determine the attitudes of cognitively normal research participants and members of the general public regarding disclosure of AD research results. DESIGN, SETTING, AND PARTICIPANTS: Participants in a longitudinal aging study (Alzheimer Disease Research Center [ADRC]) were given preintervention and postintervention surveys about disclosure attitudes. In a general public sample (The American Panel Survey), participants responded to a similar survey about disclosure attitudes.
INTERVENTIONS: Participants in the ADRC sample were randomly assigned to a group (n = 119) that read an education intervention about the usefulness of AD biomarkers or to a placebo group (n = 100) that read as its intervention general information about the ADRC. Participants in the general public sample read a brief vignette describing participation in a longitudinal AD study. MAIN OUTCOME AND MEASURE: Interest in disclosure of AD research results.
RESULTS: Cognitively normal ADRC participants (n = 219) were 60.7% (n = 133) female, 83.6% (n = 183) of white race, and reported a mean of 15.91 years of education. Twenty-nine individuals refused participation. The American Panel Survey participants (n = 1418) indicated they did not have AD and were 50.5% (n = 716) female, 76.7% (n = 1087) of white race, and reported a mean of 13.85 years of education. Overall, 77.6% of eligible participants (1583 of 2041) completed the survey in July 2014. Interest in disclosure was high among the ADRC participants (55.1% [119 of 216] were "extremely interested"). Viewing the education intervention predicted lower interest in disclosure (odds ratio, 2.01; 95% CI, 1.15-3.53; P = .02). High subjective risk of AD, a family history of AD, and minimal attendance at research meetings were associated with high interest after the intervention. In the general public, interest was lower overall (12.5% [174 of 1389] were "extremely interested"), but the subset of participants most likely to join an AD research study reported higher interest (43.5% [40 of 92] were extremely interested). CONCLUSIONS AND RELEVANCE: Experience with AD appears to increase interest in disclosure of AD research results. Learning about potential limitations of disclosure somewhat tempered interest. These findings should inform the development of disclosure policies for asymptomatic individuals in AD studies.

Entities:  

Mesh:

Year:  2015        PMID: 26501506      PMCID: PMC4694568          DOI: 10.1001/jamaneurol.2015.2875

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  31 in total

Review 1.  Return of individual research results and incidental findings: facing the challenges of translational science.

Authors:  Susan M Wolf
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

2.  Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.

Authors:  Tara T Lineweaver; Mark W Bondi; Douglas Galasko; David P Salmon
Journal:  Am J Psychiatry       Date:  2014-02       Impact factor: 18.112

3.  Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease.

Authors:  Jason Karlawish
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

4.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

5.  In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Authors:  Chester A Mathis; Lewis H Kuller; William E Klunk; Beth E Snitz; Julie C Price; Lisa A Weissfeld; Bedda L Rosario; Brian J Lopresti; Judith A Saxton; Howard J Aizenstein; Eric M McDade; M Ilyas Kamboh; Steven T DeKosky; Oscar L Lopez
Journal:  Ann Neurol       Date:  2013-04-17       Impact factor: 10.422

6.  Using AD biomarker research results for clinical care: a survey of ADNI investigators.

Authors:  Melanie B Shulman; Kristin Harkins; Robert C Green; Jason Karlawish
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

7.  Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment.

Authors:  Brian D Carpenter; Chengjie Xiong; Emily K Porensky; Monica M Lee; Patrick J Brown; Mary Coats; David Johnson; John C Morris
Journal:  J Am Geriatr Soc       Date:  2008-01-05       Impact factor: 5.562

8.  Should we disclose amyloid imaging results to cognitively normal individuals?

Authors:  Joshua D Grill; David K Johnson; Jeffrey M Burns
Journal:  Neurodegener Dis Manag       Date:  2013-02

9.  Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.

Authors:  Serena Chao; J Scott Roberts; Theresa M Marteau; Rebecca Silliman; L Adrienne Cupples; Robert C Green
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jan-Mar       Impact factor: 2.703

10.  Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.

Authors:  J Scott Roberts; Susan A LaRusse; Heather Katzen; Peter J Whitehouse; Melissa Barber; Stephen G Post; Norman Relkin; Kimberly Quaid; Robert H Pietrzak; L Adrienne Cupples; Lindsay A Farrer; Tamsen Brown; Robert C Green
Journal:  Alzheimer Dis Assoc Disord       Date:  2003 Apr-Jun       Impact factor: 2.703

View more
  19 in total

1.  Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies.

Authors:  Matthew Gabel; Jonathan Gooblar; Catherine M Roe; Natalie J Selsor; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Jul-Sep       Impact factor: 2.703

2.  Return of individual research results from genomic research: A systematic review of stakeholder perspectives.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Mwenza Blell; Isabelle Budin-Ljøsne; Lorraine Cowley; Stephanie O M Dyke; Clara Gaff; Robert Green; Alison Hall; Amber L Johns; Bartha M Knoppers; Stephanie Mulrine; Christine Patch; Eva Winkler; Madeleine J Murtagh
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

3.  Anticipated reactions to learning Alzheimer's disease biomarker results.

Authors:  Lindsay R Clark; Claire M Erickson; Erin M Jonaitis; Yue Ma; Nathaniel A Chin; Kristin Basche; Frederick B Ketchum; Carey E Gleason
Journal:  Alzheimers Res Ther       Date:  2022-06-22       Impact factor: 8.823

4.  Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing.

Authors:  Melissa J Armstrong; Gary S Gronseth; Gregory S Day; Carol Rheaume; Slande Alliance; C D Mullins
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Jul-Sep       Impact factor: 2.703

5.  Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.

Authors:  Jessica Mozersky; Pamela Sankar; Kristin Harkins; Sara Hachey; Jason Karlawish
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

Review 6.  Views on genomic research result delivery methods and informed consent: a review.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Madeleine J Murtagh
Journal:  Per Med       Date:  2021-04-06       Impact factor: 2.512

7.  Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results.

Authors:  Jessica Mozersky; Sarah Hartz; Erin Linnenbringer; Lillie Levin; Marissa Streitz; Kristin Stock; Krista Moulder; John C Morris
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis.

Authors:  Fred B Ketchum; Claire M Erickson; Nathaniel A Chin; Carey E Gleason; Nickolas H Lambrou; Susan Flowers Benton; Lindsay R Clark
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

9.  Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.

Authors:  Gwendolien Vanderschaeghe; Jolien Schaeverbeke; Rose Bruffaerts; Rik Vandenberghe; Kris Dierickx
Journal:  Alzheimers Res Ther       Date:  2017-12-02       Impact factor: 6.982

10.  Recruiting to preclinical Alzheimer's disease clinical trials through registries.

Authors:  Joshua D Grill
Journal:  Alzheimers Dement (N Y)       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.